Abstract: Etoposide is a semi-synthetic derivative of podophyllotoxin and a highly effective chemotherapeutic agent widely used against various malignancies, including small cell lung cancer, cervical cancer, and ovarian cancer. It exerts its cytotoxic effects by acting as a topoisomerase II (Topo II) poison, stabilizing the Topo II-DNA cleavage complex and inducing lethal DNA double-strand breaks (DSBs). Despite its clinical success, the efficacy of etoposide is frequently compromised by the emergence of drug resistance and the robust activation of cellular DNA repair mechanisms. Furthermore, etoposide treatment is associated with severe toxicities, most notably therapy-related secondary leukemia driven by chromosomal translocations. This review comprehensively examines the pharmacological activity, molecular mechanisms, and structure-activity relationships of etoposide. It critically addresses current limitations, focusing on the molecular basis of chemoresistance—such as drug efflux, TOP2A mutations, alternative splicing, and enhanced DNA repair. Finally, it explores future perspectives and emerging strategies to overcome drug resistance and DNA repair inhibition, including the use of DNA repair inhibitors, epigenetic modulators, natural polyphenols, CRISPR/Cas9 gene editing, and advanced nanocarrier delivery systems.
1. Introduction
Cancer remains a leading cause of mortality worldwide, necessitating the continuous development and optimization of chemotherapeutic agents. Etoposide, a semi-synthetic glycosidic derivative of podophyllotoxin (derived from the American Mayapple, Podophyllum peltatum), was first synthesized in 1966 and approved by the FDA for cancer therapy in 1983 [2][13]. It has since become a cornerstone in the treatment of numerous neoplasms, including small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), cervical cancer, ovarian cancer, lymphomas, and leukemia [1][3][11]. Etoposide functions primarily as a topoisomerase II (Topo II) poison, disrupting DNA topology management during replication and transcription, ultimately leading to cell death [3][23].
Despite its widespread clinical utility, the therapeutic window of etoposide is significantly narrowed by two major challenges: the development of acquired or intrinsic drug resistance and the induction of severe adverse effects, such as therapy-related secondary malignancies [11][20]. Cancer cells frequently deploy robust DNA repair mechanisms and alter target enzyme expression to evade etoposide-induced cytotoxicity [16]. Consequently, current research is heavily focused on understanding these resistance mechanisms and developing novel combination therapies, targeted inhibitors, and advanced delivery systems to overcome DNA repair inhibition and restore etoposide sensitivity.
2. Pharmacological Activity
Etoposide exhibits potent pharmacological activity against a broad spectrum of solid tumors and hematological malignancies. In clinical practice, it is rarely used as a single agent due to limited monotherapy efficacy and the rapid onset of resistance; instead, it is a fundamental component of combination chemotherapy regimens [11]. For instance, the combination of etoposide with platinum-based drugs (cisplatin or carboplatin) is the standard first-line therapy for SCLC and neuroendocrine carcinomas, yielding high objective response rates by synergistically enhancing DNA damage and promoting cancer cell apoptosis [11][13][19].
In cervical and ovarian cancers, etoposide is utilized in combination with other agents to manage advanced or recurrent disease [1][16]. Combination with topotecan, a Topoisomerase I (Topo I) inhibitor, has shown promise because inhibiting one topoisomerase frequently results in the compensatory overexpression of the other; dual targeting thus reduces drug resistance [1]. Etoposide is also employed in conditioning regimens for allogeneic hematopoietic stem cell transplantation and in the treatment of hemophagocytic lymphohistiocytosis [3][18].
3. Molecular Mechanism of Action
The primary molecular target of etoposide is the Topo II enzyme, which exists in mammals as two isoforms: Topo IIα (highly expressed in proliferating cells and a marker of tumor growth) and Topo IIβ (involved in transcription in both proliferating and post-mitotic cells) [1][4]. Topo II regulates DNA topology by creating transient double-strand breaks (DSBs) to allow the passage of another DNA duplex, followed by re-ligation of the broken strands [2].
Etoposide acts as a Topo II poison rather than a catalytic inhibitor. It binds to the Topo II-DNA complex, stabilizing the transient cleavage intermediate (TopoIIcc) and preventing the re-ligation step [1][3]. When cellular machineries, such as replication forks or transcription complexes, collide with these trapped TopoIIcc structures, the complexes are converted into permanent, lethal DSBs [6]. The accumulation of DSBs triggers the DNA damage response (DDR), activating sensors like ATM and ATR, which subsequently stabilize and activate the tumor suppressor p53 [13][15]. Activated p53 upregulates pro-apoptotic proteins such as Bax, leading to cytochrome c release and the activation of caspase-mediated apoptosis [8][13].
4. Structure-Activity Relationship (SAR)
Etoposide is a polycyclic compound comprising A-D rings, an E-ring, and a glycosidic moiety [4]. Its interaction with the Topo II-DNA complex is highly specific. Etoposide enters the DNA groove and interacts with specific amino acid residues of the Topo II enzyme, stabilizing the cleavable complex. The drug itself has a low affinity for free DNA and is a poor intercalator, relying heavily on the active role of Topo II to form the ternary complex [2].
Mutations in the TOP2A gene can drastically alter this interaction. For example, a single point mutation (Gly551Ser) in the DNA-gate domain of Topo II confers dual resistance to both etoposide (a poison) and ICRF (a catalytic inhibitor) by altering the allosteric properties and the etoposide-binding site in the DNA groove [9]. Furthermore, the metabolic processing of etoposide's structure plays a role in its activity and toxicity. Cytochrome P450 enzymes (e.g., CYP3A4) and myeloperoxidase metabolize etoposide into etoposide catechol and etoposide quinone. These oxidative metabolites can covalently bind to cysteine residues on critical cellular enzymes, such as CREBBP and TCPTP, inhibiting their activity and contributing to leukemogenesis [11][17].
5. Current Limitations
The clinical efficacy of etoposide is severely hindered by the development of drug resistance and significant toxicities.
Drug Resistance Mechanisms: Cancer cells utilize a multifaceted approach to survive etoposide-induced damage: 1. Drug Efflux: Overexpression of ATP-binding cassette (ABC) transporters, such as P-glycoprotein (MDR1/ABCB1), MRP2, and MRP3, actively pumps etoposide out of the cell, reducing intracellular drug concentrations [3][17]. 2. Target Alteration and Downregulation: Downregulation of TOP2A expression or mutations (e.g., Gly551Ser) directly reduce drug targets [9]. Additionally, aberrant post-translational modifications (PTMs), such as hyperphosphorylation, and intronic polyadenylation (IPA) generate truncated TOP2A splice variants that lack nuclear localization signals, rendering the cells resistant to Topo II poisons [16][22]. 3. Enhanced DNA Repair: The survival of cancer cells heavily depends on repairing etoposide-induced DSBs. Cells upregulate Non-Homologous End Joining (NHEJ) and Homologous Recombination (HR) pathways. Proteins such as Ku70/Ku80, DNA-PKcs, and the MRN complex (Mre11/Rad50/Nbs1) in conjunction with CtIP and BRCA1 rapidly process and repair Topo II-DNA adducts [2][6][15]. Tyrosyl-DNA phosphodiesterase 2 (TDP2) also plays a critical role by hydrolyzing the phosphodiester bond between Topo II and DNA after proteasomal degradation of the enzyme, rescuing the cell from lethal DSBs [2][11]. 4. MDM2 Overexpression: A single nucleotide polymorphism (SNP309) in the MDM2 promoter leads to MDM2 upregulation, which targets Topo II for proteasomal degradation, thereby decreasing the number of cleavable complexes and conferring resistance [2].
Toxicity and Secondary Malignancies: Etoposide treatment is notoriously associated with therapy-related secondary leukemia (t-AML). This is primarily driven by the Topo IIβ isoform, which mediates site-specific DNA cleavage in the breakpoint cluster region (BCR) of the Mixed-Lineage Leukemia (MLL) gene on chromosome 11q23. Faulty repair of these DSBs via NHEJ leads to chromosomal translocations and leukemogenesis [6][11][20].
6. Future Perspectives
To surmount the hurdles of drug resistance and DNA repair inhibition, several innovative therapeutic strategies are currently under investigation:
1. DNA Repair Inhibitors: Combining etoposide with inhibitors of the DNA damage response is a highly promising strategy. Inhibitors targeting PARP, DNA-PK, and DNA ligase IV can prevent the repair of etoposide-induced DSBs, synergistically enhancing cancer cell death [3][6]. Furthermore, targeting the Mre11 nuclease (e.g., with the inhibitor mirin) or DNA2 prevents the resection of 5' Topo II adducts, specifically sensitizing proliferating cancer cells to etoposide [6].
2. Epigenetic Modulation: Histone deacetylase (HDAC) inhibitors, such as trichostatin A (TSA), promote chromatin relaxation. Pretreatment with low-dose HDAC inhibitors increases the accessibility of Topo II to DNA and downregulates DNA repair proteins, thereby sensitizing resistant cancer cells to etoposide [1][2].
3. Natural Polyphenols: Naturally occurring polyphenols are being explored as modulators of etoposide activity. Compounds like Epigallocatechin gallate (EGCG) and gossypol have shown synergistic effects when combined with etoposide, enhancing apoptosis and overcoming resistance by targeting anti-apoptotic proteins (e.g., Bcl-xL) or chaperone proteins (e.g., GRP78) [8]. However, care must be taken, as some polyphenols like quercetin can act antagonistically by reducing reactive oxygen species (ROS) or inducing cell cycle arrest, allowing time for DNA repair [8].
4. Gene Editing and RNA Interference: Advanced genomic tools offer precise methods to reverse resistance. CRISPR/Cas9 combined with homology-directed repair (HDR) has been successfully utilized in preclinical models to edit mutated splice sites (e.g., TOP2A exon 19/intron 19), preventing aberrant intronic polyadenylation and restoring the expression of full-length, nuclear-localized Topo IIα [22]. Additionally, siRNA-mediated knockdown of resistance genes (such as survivin or MDM2) delivered via nanovehicles has been shown to re-sensitize resistant leukemia and glioma cells to etoposide [2][5].
5. Nanocarrier Delivery Systems: To improve the therapeutic index and reduce systemic toxicity, nanoparticle-based drug delivery systems (e.g., lipid nanoparticles, polymeric nanogels) are being developed. These systems allow for the controlled, targeted co-delivery of etoposide alongside resistance modulators (like curcumin or siRNA), ensuring optimal drug ratios at the tumor site while minimizing off-target effects [1][3][5].
In conclusion, while etoposide remains a vital chemotherapeutic agent, its future clinical utility depends on the successful integration of precision medicine approaches. By combining etoposide with targeted DNA repair inhibitors, epigenetic modulators, and advanced nanodelivery platforms, it is possible to overcome chemoresistance, mitigate toxicity, and significantly improve patient outcomes.
